Emflaza (Deflazacort) Patent Expiration, LOE Window & CMS Spending

Emflaza (Deflazacort) by Ptc Therapeutics: FDA Orange Book LOE 2026-06-07, 6 AB generics, $218.1M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPtc Therapeutics
FDA Application & PathwayN208684 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-06-07
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$218.1M
2024 Medicare Part D Spend$15.4M
2024 Medicaid Spend$202.7M
Reported Wholesale Price Change (CA SB 17)10 WAC filings (max 76.6% 2-yr change)